|
Name |
3-O-methylfunicone
|
| Molecular Formula | C20H20O8 | |
| IUPAC Name* |
methyl 3,5-dimethoxy-2-[5-methoxy-4-oxo-6-[(E)-prop-1-enyl]pyran-3-carbonyl]benzoate
|
|
| SMILES |
C/C=C/C1=C(C(=O)C(=CO1)C(=O)C2=C(C=C(C=C2OC)OC)C(=O)OC)OC
|
|
| InChI |
InChI=1S/C20H20O8/c1-6-7-14-19(26-4)18(22)13(10-28-14)17(21)16-12(20(23)27-5)8-11(24-2)9-15(16)25-3/h6-10H,1-5H3/b7-6+
|
|
| InChIKey |
WGLRJONCGNNMKL-VOTSOKGWSA-N
|
|
| Synonyms |
3-O-methylfunicone; CHEMBL3593571; Methyl 3,5-dimethoxy-2-[5-methoxy-4-oxo-6-[(E)-prop-1-enyl]pyran-3-carbonyl]benzoate; Methylfunicone; SCHEMBL902950; MEGxm0_000103; ACon0_000934; ACon1_000360; DTXSID801045493; BDBM50104668; ZINC31156764; Q15410219; NCGC00169150-03!methyl 3,5-dimethoxy-2-[5-methoxy-4-oxo-6-[(E)-prop-1-enyl]pyran-3-carbonyl]benzoate
|
|
| CAS | NA | |
| PubChem CID | 10548301 | |
| ChEMBL ID | CHEMBL3593571 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 388.4 | ALogp: | 2.7 |
| HBD: | 0 | HBA: | 8 |
| Rotatable Bonds: | 8 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 97.4 | Aromatic Rings: | 2 |
| Heavy Atoms: | 28 | QED Weighted: | 0.525 |
| Caco-2 Permeability: | -4.624 | MDCK Permeability: | 0.00003540 |
| Pgp-inhibitor: | 0.987 | Pgp-substrate: | 0.001 |
| Human Intestinal Absorption (HIA): | 0.038 | 20% Bioavailability (F20%): | 0.037 |
| 30% Bioavailability (F30%): | 0.929 |
| Blood-Brain-Barrier Penetration (BBB): | 0.228 | Plasma Protein Binding (PPB): | 74.25% |
| Volume Distribution (VD): | 0.6 | Fu: | 17.59% |
| CYP1A2-inhibitor: | 0.759 | CYP1A2-substrate: | 0.96 |
| CYP2C19-inhibitor: | 0.815 | CYP2C19-substrate: | 0.346 |
| CYP2C9-inhibitor: | 0.819 | CYP2C9-substrate: | 0.876 |
| CYP2D6-inhibitor: | 0.269 | CYP2D6-substrate: | 0.833 |
| CYP3A4-inhibitor: | 0.751 | CYP3A4-substrate: | 0.319 |
| Clearance (CL): | 7.598 | Half-life (T1/2): | 0.588 |
| hERG Blockers: | 0.02 | Human Hepatotoxicity (H-HT): | 0.522 |
| Drug-inuced Liver Injury (DILI): | 0.934 | AMES Toxicity: | 0.11 |
| Rat Oral Acute Toxicity: | 0.419 | Maximum Recommended Daily Dose: | 0.107 |
| Skin Sensitization: | 0.258 | Carcinogencity: | 0.222 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.104 |
| Respiratory Toxicity: | 0.526 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003039 | ![]() |
0.817 | D09DHY | ![]() |
0.322 | ||
| ENC003306 | ![]() |
0.767 | D02LZB | ![]() |
0.302 | ||
| ENC001897 | ![]() |
0.709 | D0A8FB | ![]() |
0.283 | ||
| ENC003307 | ![]() |
0.596 | D06GCK | ![]() |
0.283 | ||
| ENC005979 | ![]() |
0.505 | D0G8NJ | ![]() |
0.280 | ||
| ENC004340 | ![]() |
0.486 | D0J4JM | ![]() |
0.274 | ||
| ENC004806 | ![]() |
0.474 | D01FFA | ![]() |
0.271 | ||
| ENC005977 | ![]() |
0.465 | D0C1SF | ![]() |
0.270 | ||
| ENC005931 | ![]() |
0.440 | D09HDR | ![]() |
0.266 | ||
| ENC002468 | ![]() |
0.430 | D0G4KG | ![]() |
0.265 | ||